Download Files:
Ladarixin (sodium)
$300 – $2,300
Products Details
Product Description
– Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma[1].
Web ID
– HY-19519A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C11H11F3NNaO6S2
References
– [1]Matheus Silverio Mattos, et al. CXCR1 and CXCR2 Inhibition by Ladarixin Improves Neutrophil-Dependent Airway Inflammation in Mice. Front Immunol. 2020 Oct 2;11:566953.|[2]Daria Marley Kemp, et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017 Feb 28;8(9):14428-14442.
CAS Number
– 865625-56-5
Molecular Weight
– 397.32
Compound Purity
– 99.15
SMILES
– O=S(C(F)(F)F)(OC1=CC=C([C@@H](C)C([N-]S(=O)(C)=O)=O)C=C1)=O.[Na+]
Clinical Information
– Phase 3
Research Area
– Infection; Inflammation/Immunology
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– CXCR
Isoform
– CXCR1;CXCR2
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
